Background: Polycystic ovary syndrome (PCOS) is a heterogeneous disorder of reproductive, endocrine, and metabolic functions. Vitamin D has an influence on metabolic and reproductive functions. This study was designed to explore the levels of free 25 hydroxycholecalciferol [25(OH)-D] in PCOS patients. We also aimed to clarify the impact of vitamin D supplementation on cardio-metabolic status, androgen profile, and clinical features of PCOS. Results: Our results revealed significant lower levels of serum 25(OH)-D in PCOS women compared with healthy controls. Even more importantly, our results reported that 25(OH)-D levels were negatively correlated with cardiometabolic risk factors, androgenic profile, and clinical features of PCOS. Stepwise multiple linear regression analysis revealed that carotid intima-media thickness (CIMT), fasting serum insulin (FSI), and fasting plasma glucose (FPG) were the main predictors of 25(OH)-D levels among other clinical and laboratory biomarkers. Considering the impact of VD supplementation in the PCOS group, there were significant improvements of cardio-metabolic risks, PCOS phenotype, and androgenic profile. Even more important, these results are associated with increasing 25(OH)-D serum levels after VD supplementations. Logistic regression analysis observed that androstenedione, FSI, and hirsutism score were independent predictors of response to VD supplementation. Conclusion: The supplementation of VD for 12 weeks improved the cardio-metabolic and androgenic profiles of PCOS. Furthermore, VD supplementation could be a promising treatment of PCOS and its associated morbidity in PCOS-deficient women. Trial registration: NCT04117750
Background
Polycystic ovarian syndrome (PCOS) is a heterogeneous disorder affecting 5-10% of women of reproductive age [1] . It is a disorder that affects the reproductive, endocrine, and metabolic functions and is the leading cause of chronic anovulation leading to infertility [2] .
PCOS is characterized by hyperandrogenism, chronic oligo or anovulation, and polycystic ovaries [3] . Hyperandrogenism, in particular, is a hallmark feature of PCOS because it is strongly implicated in the genesis of the disorder [4] and is also associated with metabolic derangements that contribute to the underlying pathophysiology [5] . Also, it is associated with cardiovascular risk factors including obesity, insulin resistance (IR), dyslipidemia, endothelial dysfunction, and metabolic syndrome [2, 5] .
Vitamin D (VD) is a fat-soluble vitamin that is naturally present in very few foods and available as a dietary supplement. It is a steroid hormone with pleiotropic effects. In addition to the main effects of VD on the bone and calcium metabolism, it has other roles in the body, including modulation of cell growth, neuromuscular and immune function, and reduction of inflammation [6] .
VD deficiency is now recognized as a pandemic disease. Its prevalence varies according to geographic location, season, ethnicity, and the standard laboratory value of what is considered normal, deficient, and insufficient. VD deficiency is a risk factor for hypertension, diabetes, and various cancers [7] . Accumulating evidences suggest that VD deficiency might be a causal factor in the pathogenesis of IR and the metabolic syndrome in PCOS [8] . Carotid intima-media thickness (CIMT) measured by ultrasound is a noninvasive, safe, low-cost, reproducible, and wellvalidated marker of preclinical atherosclerosis [9, 10] .
PCOS is the most frequent endocrine disorder among women of a reproductive age and VD deficiency is a key problem in PCOS patients conversely; the basic mechanisms underlying the favorable effects of vitamin D in PCOS are still obscure. Resolving this mechanism may provide insight into the pathophysiology of this syndrome. It can also offer a new therapeutic option for PCOS women. Thus, the present study was designed to explore the levels of free 25 hydroxyvitamin D [25(OH)-D] in PCOS patients. We also aimed to clarify the impact of vitamin D supplementation cardio-metabolic status, androgen profile, and clinical features of PCOS.
Methods
This placebo-controlled trial comprised 95 women with PCO recruited from Outpatient Clinics of the Endocrinology Unit of Internal Medicine and Obstetrics and Gynecology Departments, Faculty of Medicine, Zagazig University, Egypt, and 50 healthy women matched to PCOS women as regards age and ethnic origin.
The diagnosis of PCOS was based on the 2004 revised Rotterdam criteria [11] . All women underwent a menstrual history and thorough clinical examination. All patients were assessed at the study start on the third day of a spontaneous or progesterone-induced menstrual cycle. Anthropometric measures were estimated, including waist/hip ratio, height, and weight and then we calculated the body mass index (BMI). We estimated the hirsutism score according to Ferriman and Gallwey [12] .
.Ovarian volume and antral follicular count (AFC) were evaluated by transvaginal ultrasound (TVS).
PCOS patients were randomized divided into an intervention group (n = 55) who received vitamin D supplements (42,000 IU oral vitamin D per week and 500 mg calcium carbonate per day for 12 weeks) and nonintervention group (n = 40) who received 500 mg calcium carbonate per day for 12 weeks.
The exclusion criteria for all women included a history of hyperandrogenic states (such as nonclassic congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome, 21-hydroxylase deficiency, or hyperprolactinemia), DM, hypertension, liver, kidney, or thyroid diseases. In addition, subjects on non-steroidal anti-inflammatory drugs and multivitamins, as well as patients treated with hormone replacement therapy.
At the start of the study, the participants were asked to maintain their usual diet and level of physical activity throughout the study period as well as not to receive any lipid-lowering medications and medications that might affect their reproductive physiology during the 12-week intervention.
At baseline and at the endpoint of the 12 weeks of study, anthropometrical measurements were estimated and blood samples were collected for biochemical analyses. Written informed consent was taken from all of the participants after explaining details and benefits as well as risks to them. The ethical committee of the Faculty of Medicine, Zagazig University, approved our study protocol.
Sampling of blood
Blood samples were drawn from all subjects during the early follicular phase of the menstrual cycles. One milliliter was collected into tubes containing fluoride for fasting plasma glucose (FPG). A second remaining part underwent immediate serum separation and was stored at − 20°C until the serum analysis. Calcium, phosphate, and albumin were measured. Total cholesterol, highdensity lipoprotein (HDL) cholesterol, and triglyceride levels were determined using routine enzymatic methods (Spinreact, Girona, Spain). Low-density lipoprotein (LDL) cholesterol levels were calculated using the Friedewald formula [13] .
Immunochemical assays
We measured prolactin, FSH, and LH levels via chemiluminescence immunoassays (CLIA) provided by (Immunospec Corporation, CA, USA). Serum high-sensitivity Creactive protein (hs-CRP) concentrations were measured using high sensitivity enzyme-linked immunosorbent assays (ELISA) (Biosource, Nivelles, Belgium). We determined fasting insulin, FSH, LH, total and free testosterone, sex hormone-binding globulin (SHBG) levels using ELISA kits (DRG International, USA). We calculated insulin resistance (IR) with the homeostatic model assessment-IR (HOMA-IR) index, which is defined as fasting serum insulin (FSI) value (μU/ml) × fasting plasma glucose value (mg/dl)/405. The B cell function was calculated using HOMA-B as (× 20 (fasting insulin μU/mL)/ (fasting glucose (mmol/l) − 3.5) [14] .
Determination of serum vitamin D levels
Serum concentrations of 25(OH)-D were tested using enzyme-linked immunosorbent assay, [Cat No. EQ 6411-9601, Euroimmun Medizinische Labordiagnostika AG, Germany]. Current recommendations define VD deficiency as serum 25(OH)-D levels less than 20 ng/ml and VD insufficiency less than 30 ng/ml [15] .
Carotid ultrasonography
Carotid artery atherosclerosis was determined by one examiner for all patients across all six sites, using highresolution B-mode ultrasound (M-Turbo®, SonoSite, Washington, Bothell, USA), according to the American Society of Echocardiography protocol [16] .
Statistical analysis
Data analyses were done with a statistical package for the social sciences software (SPSS Version 17, Chicago, Illinois). Data were expressed as mean ± standard deviation (SD). The relationships of serum 25(OH)-D levels with clinical and laboratory parameters among PCOS patients were tested with the Pearson correlation. A stepwise multiple linear regression analysis was done to detect the main predictors of serum 25(OH)-D levels in the PCOS group. Logistic regression analysis was performed to determine the predictor biomarker associated with VD supplementation among PCOS patients. The appropriate sample size and power of the study were determined using PAWE-3D [17] . We considered P to be significant at < 0.05 with a 95% confidence interval (CI).
Results
The final total numbers of PCOS women enrolled in this study were 95, at the beginning of the study, 110 women with PCOS were included in the trial; 60 women with PCOS in the intervention group and 40 PCOS patients in the non-intervention group. Finally, 55 patients of the intervention group and 40 PCOS patients of the nonintervention group completed our study. Thus, we excluded all subjects who did not complete this study. Of note, there were no adverse effects of VD supplementation during the intervention.
Clinical and biochemical characteristics of the studied groups
In the PCOS group, we found significant higher levels of waist/hip ratio, systolic, and diastolic blood pressure, total cholesterol, triglycerides, LDL cholesterol, FPG, FSI, and HOMA-IR compared to the healthy control group. PCOS laboratory markers including total testosterone, free testosterone, androstenedione, DHEA-S, hirsutism score, ovarian volume, FSH, LH, LH/FSH, and antral follicle count (AFC) values were significantly high in PCOS cases compared with controls.
Additionally, the PCOS group had significantly higher levels of serum P, albumin, serum ALP, and CIMT compared to the control group. On the contrary, we detected significant lower values of serum 25(OH)-D, serum Ca, SHBG, HDL, and HOMA-B levels in PCOS patients compared to the control group. Moreover, we observed significant higher levels of inflammatory markers; hs-CRP, WBC, and neutrophil counts in PCOS cases compared to controls (P ˃ 0.05), (Table 1) .
Pearson correlation between serum 25(OH)-D (ng/ml) levels and clinical and laboratory parameters among PCOS women
Serum 25(OH)-D levels were negatively correlated with systolic blood pressure ( Fig. 1 ), serum triglycerides ( Fig. 2 ), HOMA-IR ( Fig. 3 ), FSI (Fig. 4 ), and BMI ( Fig. 5 ). Also, serum 25(OH)-D concentrations were negatively correlated with CIMT (( Fig. 6 ), free testosterone ( Fig. 7) , AFC ( Fig. 8 ), ovarian volume ( Fig. 9 ), and hs-CRP ( Fig. 10 ). However, the hirsutism score ( Fig. 11 ) was non-significant correlated with serum 25(OH)-D levels.
A stepwise multiple linear regression analysis in PCOS groups
In PCOS group, stepwise multiple linear regression analysis revealed that CIMT, FSI, and FPG were the main predictors of serum 25(OH)-D levels among other clinical and laboratory biomarkers ( Table 2 ).
The impact of vitamin D supplementations on clinicmetabolic status and androgenic profile among the studied group
In the non-intervention group (n = 40) after 12 weeks of trial, our results revealed a significant increase of BMI, TC, LDL, hs-CRP, WBC, and neutrophil counts, whereas HDL level was significantly decreased.
Considering the impact of VD supplementation in the intervention group (42,000 IU oral vitamin D per week and 500 mg calcium carbonate per day for 12 weeks), on body composition parameters, BMI and WHR were significantly decreased. Moreover, cardio-metabolic risks were improved after VD supplementations (Table 3) .
Regarding the PCOS phenotype, androgenic profile, and inflammatory markers, there were significantly decreased values after the intervention. Even more important, 25(OH)-D serum levels were increased after VD supplementations ( Table 3) .
Assessment of the power of VD supplementation to improve cardio-metabolic risk and androgenic markers of women with PCOS Logistic regression analysis was performed to detect the main predictors of cardio-metabolic biomarkers associated with VD supplementation among PCOS patients. Our findings revealed that among clinical and laboratory features of PCOS, androstenedione, FSI, and hirsutism score were independent predictors of improvement of VD supplementation with odds ratios of 0.253, 1.199, and 1.330, respectively (Table 4 ).
Discussion
As a matter of fact, PCOS is the most common ovarian disorder that affects 6-10% women worldwide [1] and accounts for 70% of cases of anovulatory infertility. PCOS is a set of reproductive and metabolic symptoms associated with an imbalance of reproductive hormones in women [2] .
The pandemic of VD deficiency represents a major public health concern, as this disorder is associated with an increased risk of medical comorbidities contributing to a significant rise in mortality. There are intriguing reports suggesting that VD deficiency is more prevalent among women with PCOS [18] . Few studies explored the association between VD deficiency with hirsutism score, IR, and obesity in PCOS [19] . Because the current treatment of PCOS is still suboptimal, and cardiometabolic diseases are the common cause of death all over the world, we aimed in the present study to investigate the levels of 25(OH)-D in PCOS patients. We also aimed to clarify the impact of vitamin D supplementation cardio-metabolic status, androgen profile, and clinical features of PCOS. In order to assess the risk of cardiovascular disease among PCOS, our results revealed that the cardiometabolic factors; systolic blood pressure, TC, TG, LDL cholesterol, FPG, 2-h plasma glucose, FSI, HOMA-IR, and CIMT were significantly high in PCOS compared to control group. Our previous experience also suggested that PCOS women had higher values of parameters of hyperglycemia and dyslipidemia as well as obesity indices [20] [21] [22] .
Our findings are in concordance with Glueck et al. who found that PCOS patients are at an increased risk of metabolic syndrome and cardiovascular risk factors in later life [23] .
Supporting our results, Zhao et al. detected a high risk of coronary heart disease in PCOS [24] . Moreover, [27] .
In order to better elucidate the levels of inflammatory markers in PCOS. In our research, we found significant higher levels of inflammatory markers; WBC, neutrophil as well as hs-CRP in PCOS cases compared to controls.
Similar to these results, our previous finding showed that PCOS patients had significant higher values of inflammatory biomarkers including serum procalcitonin, hs-CRP, WBC, and neutrophil counts compared to healthy women [20] [21] [22] . Altogether, these data point to VD acts to lower systemic inflammation in general by interacting with transcription and expression of cytokine genes [28] [29] [30] .
Omics studies have indeed demonstrated that VD could under-regulate the activation of nuclear factor-κB [30] , which plays a regulatory role for pro-inflammatory cytokine generation associated with the resistance of insulin [31, 32] . We in this study attempted to explore the levels of serum 25(OH)-D in PCOS, we found significant lower levels of serum 25(OH)-D in PCOS women compared with healthy controls. Even more importantly, our results reported that 25(OH)-D levels were negatively correlated with cardio-metabolic risk including, systolic blood pressure, serum triglycerides, HOMA-IR, FSI, BMI, CIMT, free testosterone, AFC, ovarian volume, and hs-CRP.
Our findings are in concordance with Wehr et al. hypovitaminosis D which was common in PCOS women [33] . Similar results were described in Hahn et al. study which was conducted on women with PCOS, and they found lower levels of serum 25(OH)-D in PCOS women [34] .
In that context, a study conducted by Jia et al. observed that the serum concentration of vitamin D is associated with the risk of PCOS. Nonetheless, they did not observe any improvement of clinical and laboratory features after vitamin D3 supplementation for women with PCOS [35] .
In contrast, a study by Panidis et al. [36] found no significant difference of serum 25(OH)-D concentrations between women with PCOS and controls.
Supporting our results, Li et al. found that metabolic risk factors were associated with lower levels of serum 25(OH)-D in PCOS women [37] . Additionally, Wehr et al. [33] observed that the serum 25OH-D level is positively correlated with insulin sensitivity and negatively correlated with IR in women with PCOS.
In earlier published studies conducted in our region, Middle East [38] , Zhang et al. observed low VD in diabetes and the possible mechanisms for this association may include the presence of vitamin D receptors in pancreatic beta cells to which circulating vitamin D binds [39] . In addition, VD has been well recognized for its role in regulating extracellular calcium flux, and insulin secretion is known as a calcium-dependent process [40] .
Similar to our results, some studies report inverse associations between serum 25(OH)-D levels and testosterone among women with PCOS [33, [41] [42] [43] .
Our finding adds to the growing body of evidence implicating that women with PCOS tend to have decreased vitamin D levels, and vitamin D deficiency has been correlated with increased IR, BMI, total testosterone, and DHEA-S [34] .
There is scattered evidence for the role of VD treatment in improving various clinical parameters in vitamin D-deficient women with PCOS including glucose intolerance, hypertension, and androgen levels [43, 44] .
The main finding in the current study explored the impact of VD supplementations (42,000 IU oral vitamin D per week and 500 mg calcium carbonate per day for 12 weeks) on serum lipids and glucose parameters.
The current study revealed that in the PCOS group, after VD supplementation, there were significant improvements of glycemic parameters including FPG, FSI, HOMA β, and HOMA-IR, compared to PCOS women at baseline of the study as well as an improvement of obesity indices BMI and WHR.
Similar results observed by Pal et al. found that VD supplementation has been shown to improve blood pressure and decrease IR, total testosterone, and androstenedione levels in vitamin D-deficient women with PCOS [43] .
Supporting our results, in a study by Wehr et al., PCOS women receiving weekly 20,000 IU of vitamin D3 for 24 weeks demonstrated a significant decrease in triglycerides at 12 weeks and 24 weeks [33] .
Our findings are in concordance with Kotsa et al. showed that triglyceride level significantly decreased and HDL significantly increased in 15 obese women with PCOS after they received alfacalcidol 1 g/d for 3 months [45] . Regarding the PCOS phenotype, androgenic profile, and inflammatory markers, there were significantly decreased values after the intervention. Even more important, 25(OH)-D serum levels were increased after VD supplementations.
Interestingly, Yildizhan et al. found that the administration of high doses of vitamin D led to the attenuation of hyperandrogenism and menstrual disturbances in women with PCOS. Moreover, treatment of low concentrations of 25(OH)-D should be kept in mind during managing obese women with PCOS [42] .
Similar results were described in Selimoglu et al. study conducted on PCOS patients vitamin D supplementation has been shown to improve cardio-metabolic risks and androgenic profile in vitamin D-deficient women with PCOS [44] .
Against our results, Pal and colleagues demonstrated that 3 months of daily oral supplementation of vitamin D (8533 IU) and calcium (530 mg) did not influence IR [43] .
Furthermore, regarding the lipid profile, we observed that supplementation with VD had significant effects on the lipid profile.
In our research, we investigated PCOS women for assessment and the influence of VD supplementation on inflammatory biomarkers; in hs-CRP and neutrophil count, there was a highly significant decrease of inflammatory biomarker Moreover, logistic regression analysis was performed to detect predictors associated with VD supplementation among PCOS cases. Of note, logistic regression analysis revealed that among clinical and laboratory features of women with PCOS, androstenedione, FSI, and Hirsutism score were independent predictors of response to VD supplementation.
The only dropout of our study was that not all the enrolled patients in our study complete the trial as the final total number of women enrolled in this study was 55 patients of the intervention group and 40 PCOS patients of the non-intervention group. Thus, we excluded all subjects who did not complete this study. Of note, there were no adverse effects of VD supplementation during the intervention.
The limitations of the study
As we mention previously in the present study, VD levels vary according to season and region; thus, we should investigate our study in different seasons and should be multicenter to obtain more accurate results, but we will do this in the next studies.
Conclusion
We found that serum levels of 25(OH)-D were decreased in PCOS patients; moreover, it is negatively correlated to measures of adiposity, insulin resistance, and hs-CRP as well as clinical and laboratory markers of PCOS. Stepwise multiple linear regression analysis revealed that CIMT, FSI, and FPG were the main predictors of 25(OH)-D levels among other clinical and laboratory biomarkers. Considering the controversy about the effects of VD supplementation on inflammatory and metabolic disorders, our novel findings revealed the favorable effect of VD supplementation on an inflammatory biomarker, clinical feature, and androgenic profile of PCOS as well as cardio-metabolic risk factors. Furthermore, VD supplementation could be a promising treatment of PCOS and its associated morbidity in PCOS-deficient women. 
